Dr. Susanna Ulahannan, MD
Claim this profileUniversity of Oklahoma Health Sciences Center
Studies Colorectal Cancer
Studies Solid Tumors
24 reported clinical trials
45 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
dMMR positive
2Solid Tumors
Stage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Susanna Ulahannan, MD is currently running
TTI-101 Combination Therapy
for Liver Cancer
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohort A Phase 2 are to assess response, progression, survival, and pharmacokinetics. The primary objectives of Cohorts B and C Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, or unresectable HCC and to determine the MTD and/or RP2D of TTI-101 when used in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C). The primary objectives of Cohorts B and C Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohorts B and C Phase 2 are to assess response, progression, survival, and pharmacokinetics.
Recruiting2 awards Phase 1 & 2
LY4066434
for Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Recruiting1 award Phase 14 criteria
More about Susanna Ulahannan, MD
Clinical Trial Related6 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Susanna Ulahannan, MD has experience with
- Nivolumab
- Pembrolizumab
- Atezolizumab
- Cetuximab
- ZEN003694
- TPST-1495
Breakdown of trials Susanna Ulahannan, MD has run
Colorectal Cancer
Solid Tumors
Thyroid Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Susanna Ulahannan, MD specialize in?
Susanna Ulahannan, MD focuses on Colorectal Cancer and Solid Tumors. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Susanna Ulahannan, MD currently recruiting for clinical trials?
Yes, Susanna Ulahannan, MD is currently recruiting for 10 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Susanna Ulahannan, MD has studied deeply?
Yes, Susanna Ulahannan, MD has studied treatments such as Nivolumab, Pembrolizumab, Atezolizumab.
What is the best way to schedule an appointment with Susanna Ulahannan, MD?
Apply for one of the trials that Susanna Ulahannan, MD is conducting.
What is the office address of Susanna Ulahannan, MD?
The office of Susanna Ulahannan, MD is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.